ReviewJournal of translational medicine2011
Biomarkers in T cell therapy clinical trials.
Review in Journal of translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Trial
- Evaluation of SLOG/TCI-III pediatric system on target control infusion of propofol.Journal of translational medicine · 2011Trial
- A 38-color spectral panel for cost efficient characterization of T cell therapy products.Cytotherapy · 2026Article
- HosTIL territory: mapping the landscape of toxicity in TIL therapy.Journal for immunotherapy of cancer · 2026Review
- CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.PLoS pathogens · 2022Article
- Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial.Frontiers in medicine · 2022Article
- Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells.Cytotechnology · 2018Article
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.Journal for immunotherapy of cancer · 2016Review
- High-content molecular profiling of T-cell therapy in oncology.Molecular therapy oncolytics · 2016Review
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.Blood · 2015Review
- Towards a commercial process for the manufacture of genetically modified T cells for therapy.Cancer gene therapy · 2015Review
- Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.Leukemia · 2015Review
- Current advances in T-cell-based cancer immunotherapy.Immunotherapy · 2014Review
- Adoptive immunotherapy for cancer or viruses.Annual review of immunology · 2014Review
- In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients.Oncology letters · 2013Article
- Adoptive immunotherapy of advanced melanoma.Current treatment options in oncology · 2012Review
- New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.Journal of translational medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell therapy represents an emerging and promising modality for the treatment of both infectious disease and cancer. Data from recent clinical trials have highlighted the potential for this therapeutic modality to effect potent anti-tumor activity. Biomarkers, operationally defined as biological parameters measured from patients that provide information about treatment impact, play a central role in the development of novel therapeutic agents. In the absence of information about primary clinical endpoints, biomarkers can provide critical insights that allow investigators to guide the clinical development of the candidate product. In the context of cell therapy trials, the definition of biomarkers can be extended to include a description of parameters of the cell product that are important for product bioactivity. This review will focus on biomarker studies as they relate to T cell therapy trials, and more specifically: i. An overview and description of categories and classes of biomarkers that are specifically relevant to T cell therapy trials, and ii. Insights into future directions and challenges for the appropriate development of biomarkers to evaluate both product bioactivity and treatment efficacy of T cell therapy trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.